Dr. Dunsire joins the board with over 30 years of experience leading large organizations in the biopharmaceutical, oncology and other specialty industries. Most recently, she retired from her role as president and chief executive officer of
H. Lundbeck A/S, a biopharmaceutical company specializing in developing and delivering transformative therapies for brain diseases. Prior to that, she held executive leadership roles for several pharmaceutical companies including XTuit Pharmaceuticals, FORUM Pharmaceuticals, Millennium: The Takeda Oncology Company and Millennium Pharmaceuticals. Dr. Dunsire started her career as a primary care physician in Johannesburg, South Africa. Dr. Dunsire currently serves on the boards of directors of Ultragenyx Pharmaceutical Inc. She received her medical degree from the University of Witwatersrand in Johannesburg, South Africa.